Cipla gets four USFDA observations for three Goa facilities

By: |
New Delhi | Published: September 30, 2016 3:16:14 PM

Drug firm Cipla today said the US health regulator has issued four observations across its three manufacturing facilities in Goa after the inspection.

Drug firm Cipla today said the US health regulator has issued four observations across its three manufacturing facilities in Goa after the inspection. (Express Photo)Drug firm Cipla today said the US health regulator has issued four observations across its three manufacturing facilities in Goa after the inspection. (Express Photo)

Drug firm Cipla today said the US health regulator has issued four observations across its three manufacturing facilities in Goa after the inspection.

“United States Food and Drug Administration (USFDA) recently concluded audit of our three manufacturing facilities in Goa and has issued four observations across these three facilities,” Cipla said in a filing to BSE.

These observations were primarily procedural in nature and the company has already responded to the same, it added.

The company, however, did not provide any details of the observations.

“We continue to operate our facilities with a high level of compliance and control,” Cipla said.

The stock was trading at Rs 581.55 in the afternoon trade on BSE, down 3.22 per cent from its previous close.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Next Stories
1Can Airtel adjust Rs 3k crore against licence fees, high court asks government
2Bajaj Auto workers to go on one-day hunger strike
3SC notice to Essar Steel in Rs 480-crore purchase tax case